Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across therapeutic areas–cardiometabolic health, oncology, immunology and neuroscience–drives our unprecedented commitment to our domestic manufacturing build-out.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely

Eli Lilly said Wednesday it will build three manufacturing plants in the United States to make the key raw ingredients in its medicines, a push to bring home a critical part of the pharmaceutical supply chain that largely comes from foreign sources.

The pharmaceutical company expects the expansion will create thousands of jobs.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,

The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug. The ad,

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States: New sites in Research Triangle Park and Concord,